Aeluma, Inc. (ALMU): Jonathan Klamkin, our President, Chief Executive Officer, and Chairman of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that provided for…

Aeluma (ALMU) reported Q4 2026 revenue of $582,000 and a GAAP net loss of $4 million, or $0.22 per share. Full-year revenue was $4.5 million, down from $4.7 million in 2025. The company is shifting focus to the AI datacom market, investing in manufacturing and hiring, with $56 million in cash reserves. It expects $2.3 million in government revenue for 2027 and is pursuing additional contracts and partnerships.

Aeluma, Inc. (ALMU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aeluma Announces Fourth Quarter and Full Fiscal Year 2026 Financial Results Signed CHIPS Letter of Intent for up to $30 Million for AI and Advanced Computing Executed New Strategic Agreement With Sumitomo Chemical Advanced Technologies to Expand Relationship and Incr

Aeluma stock rose 7.0% in pre-market trading after announcing a partnership with Sumitomo Chemical Advanced Technologies to develop and manufacture photonics wafers for AI datacom. The company is set to report Q4 and full-year 2026 earnings on September 16. The sole analyst's price target of $30.50 suggests significant upside from current levels.

MarketBeat highlights NVIDIA’s broader photonics investment and says the global photonics market is about $1.25T, growing mid-single digits through the next decade, with silicon photonics rising ~30% annually. It profiles Aeluma (NASDAQ: ALMU), citing quantum-dot lasers and a manufacturing method that grows optical-quality substrate on silicon. The article notes Aeluma is pre-revenue, seeks data-center/defense partnerships for design wins and prototype certifications, and targets production and

Aeluma (NASDAQ: ALMU) said the U.S. Department of Commerce announced proposed CHIPS Act incentives of more than $2 billion for nine companies to accelerate quantum computing, shifting from R&D to manufacturing. Aeluma supported one company that signed a letter of intent, with involvement contingent on a subcontract. Aeluma cited its scalable wafer platform and recent U.S. contracts for quantum materials and lasers.

Freedom Broker downgraded Amgen to Hold from Buy but raised its price target to $470 from $450, a 4.4% increase. The new target implies a 2.1% upside from Amgen's Nov 6 close of $460.42. Recent analyst price targets for Amgen range from $435 to $530.